Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T28713
|
||||
Former ID |
TTDC00010
|
||||
Target Name |
Serine/threonine-protein kinase Chk2
|
||||
Gene Name |
CHEK2
|
||||
Synonyms |
CHK2; Cds1; RAD53; CHEK2
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
BioChemical Class |
Kinase
|
||||
Target Validation |
T28713
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.11.1
|
||||
Sequence |
MSRESDVEAQQSHGSSACSQPHGSVTQSQGSSSQSQGISSSSTSTMPNSSQSSHSSSGTL
SSLETVSTQELYSIPEDQEPEDQEPEEPTPAPWARLWALQDGFANLECVNDNYWFGRDKS CEYCFDEPLLKRTDKYRTYSKKHFRIFREVGPKNSYIAYIEDHSGNGTFVNTELVGKGKR RPLNNNSEIALSLSRNKVFVFFDLTVDDQSVYPKALRDEYIMSKTLGSGACGEVKLAFER KTCKKVAIKIISKRKFAIGSAREADPALNVETEIEILKKLNHPCIIKIKNFFDAEDYYIV LELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEE DCLIKITDFGHSKILGETSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFIC LSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKKLLVVDPKARFTTEEA LRHPWLQDEDMKRKFQDLLSEENESTALPQVLAQPSTSRKRPREGEAEGAETTKRPAVCA AVL |
||||
Drugs and Mode of Action | |||||
Inhibitor | 2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine | Drug Info | [527477] | ||
5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole | Drug Info | [527477] | |||
CCT-241533 | Drug Info | [525351] | |||
Chk2 inhibitor II | Drug Info | [529213] | |||
compound 25b | Drug Info | [531897] | |||
DEBROMOHYMENIALDISINE | Drug Info | [527140] | |||
PV-1019 | Drug Info | [525367] | |||
Modulator | XL844 | Drug Info | [1572591] | ||
Pathways | |||||
KEGG Pathway | Cell cycle | ||||
p53 signaling pathway | |||||
HTLV-I infection | |||||
Pathway Interaction Database | ATM pathway | ||||
FOXM1 transcription factor network | |||||
p53 pathway | |||||
PLK3 signaling events | |||||
Reactome | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | ||||
G2/M DNA damage checkpoint | |||||
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | |||||
WikiPathways | DNA Damage Response | ||||
ATM Signaling Pathway | |||||
Integrated Pancreatic Cancer Pathway | |||||
Prostate Cancer | |||||
Integrated Breast Cancer Pathway | |||||
Integrated Cancer pathway | |||||
Cell Cycle | |||||
miRNA Regulation of DNA Damage Response | |||||
References | |||||
Ref 525351 | CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Res. 2011 Jan 15;71(2):463-72. | ||||
Ref 525367 | Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. | ||||
Ref 527140 | Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21.Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. | ||||
Ref 527477 | J Med Chem. 2005 Mar 24;48(6):1873-85.Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. | ||||
Ref 529213 | Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. Epub 2007 Dec 11.A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.